This advanced technology promises to revolutionise cancer treatment, offering patients more precise, effective, and potentially life-saving care, according to Paula Agbowu, the hospital’s director of engineering services.

“Coming up is the acquisition of a linear accelerator machine that will be used to help treat some of our oncology cases,” Christine Greenidge, the hospital’s chief operating officer, said during this week’s Pulse Radio programme.

The new linear accelerator, expected to be operational by year’s end, represents a significant upgrade from the hospital’s current cobalt-based technology. It will enable oncologists to deliver highly targeted radiation therapy, potentially improving outcomes and reducing side effects for cancer patients, according to Agbowu.

The director of engineering services highlighted the transformative impact this acquisition will have on patient care.

“The actual linear accelerator will mean that the kind of treatment that we will be able to afford our patients will be much more enhanced than the treatment that we had before,” she stated. “This is an upgrade and a step up from what we had in place before.”

The installation of this sophisticated equipment is part of a broader £130 million investment in the hospital’s infrastructure and technology. This substantial funding, announced earlier this year by the Ministry of Health, underscores the government’s commitment to enhancing healthcare services across the island. The first tranche of funding is expected to be released in the coming weeks, Agbowu revealed.

The hospital is undertaking comprehensive infrastructure improvements, including modifications to the treatment bunker, electrical systems, and IT infrastructure. Crucially, the QEH is investing in its staff to ensure they can maximise the potential of this new technology. Physicists, radiographers, and oncologists are already engaged in intensive training programmes to familiarise themselves with the linear accelerator’s advanced capabilities.

Meanwhile, the QEH is undertaking an ambitious initiative to transform healthcare delivery, making it more accessible and efficient for patients.

At the heart of this overhaul is an expansion of telehealth services, allowing remote monitoring of patients with chronic conditions such as congestive heart failure. This innovative approach enables medical staff to track vital signs from patients’ homes, reducing the need for frequent hospital visits and allowing for timely interventions.

QEH is also transitioning to electronic medical records, streamlining appointment management and granting patients easier access to their health information. The comprehensive upgrade extends to health information systems, enhancing both patient care and data protection. These initiatives are part of the $130 million capital expenditure programme designed to acquire new technology and upgrade existing systems at the hospital.

The post QEH on track to revolutionise cancer care with linear accelerator appeared first on Barbados Today.

The product is a generic equivalent of Alphagan P Ophthalmic Solution, 0.1%, of AbbVie Inc. It will be manufactured at Lupin's Pithampur facility in India.

Brimonidine Tartrate Ophthalmic Solution, 0.1% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Read also: Lupin alliance partner ForDoz gets USFDA nod for Doxorubicin Hydrochloride Liposome Injection

Open-Angle Glaucoma is the most common form of glaucoma, a group of eye conditions that damage the optic nerve, leading to vision loss. This damage is often caused by abnormally high pressure in the eye (intraocular pressure), though normal-pressure glaucoma can also occur.

Medical Dialogues team had earlier reported that Lupin Limited had received USFDA nod for its Abbreviated New Drug Application for Travoprost Ophthalmic Solution USP, 0.004%(Ionic Buffered Solution). Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.

Read also: Lupin bags USFDA nod for Travoprost Ophthalmic Solution

Brimonidine Tartrate Ophthalmic Solution (RLD Alphagan P) had an estimated annual sales of USD178.5 million in the U.S. (IQVIA MAT June 2024).

Lupin Limited is a global pharmaceutical Company headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company has a presence in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally.

Also Read:6 medicines of Alembic Pharma received USFDA nod during Q2FY24

As parents, we understand the importance of protecting our children’s eyes from the sun’s harmful rays, but what about the harmful effects of blue light? Blue light, a colour in the visible light spectrum, is everywhere. Believe it or not, sunlight...

Monkeypox is caused by the Orthopoxvirus, which is related to the smallpox family of disorders native to the African continent. However, this virus has recently spread throughout Africa and to some countries in Europe. Monkeypox (mpox)is capable...

“Eating at least one well-balanced meal each day can go a long way in ensuring that you get the right amount of nutrients and minerals your body needs to function”

View the full post Foods that boost mood and brain health  on NOW Grenada.

Dr Kenneth Connell, the deputy dean of recruitment and outreach in the faculty of medical sciences at the University of the West Indies Cave Hill Campus, has been appointed as the president of the HCC, a not-for-profit Caribbean non-communicable disease (NCD) alliance of over 100 health and non-health civil society organisations, whose vision is to reduce death and disability from chronic diseases among Caribbean people.

In his first address as HCC president, Dr Connell outlined a multi-pronged approach to improve public health across the Caribbean. “Small island states are now under attack from the deadly triad of cardiovascular disease, climate change, and commercial determinants of health. The HCC must now position itself to be innovative, culturally sensitive, and very responsive to the needs of our stakeholders, especially the individual citizens of our one Caribbean community,” he stated.

At the heart of Dr Connell’s plan is a push for robust school nutrition policies. These aim to instill healthy eating habits in young people, potentially stemming the rise of obesity and related NCDs. Alongside this, he proposes the introduction of octagonal front-of-package warning labels on food products, a measure that has shown promise in other parts of the world in guiding consumers towards healthier choices.

The new president, also a consultant physician at the Queen Elizabeth Hospital and consultant-in-charge of the hospital’s resistant hypertension clinic, is also setting his sights on the food industry, with a particular focus on eliminating trans fatty acids from ultra-processed foods. This initiative could significantly reduce the risk of heart disease across the Caribbean.

“I am both passionate, and unconditionally committed, to advancing our region as a model health space for the world,” he said.

The insurance company Sagicor, which has had a longstanding partnership with the HCC, has welcomed the plan by the new president.

“Sagicor looks forward to future collaborations with the HCC as we seek to help our communities improve the management of chronic diseases in our region,” Paul Inniss, executive vice president of Sagicor Life Inc (Barbados), said.

(PR)

The post New HCC head tackles Caribbean’s ‘deadly triad’ appeared first on Barbados Today.